This includes Pfizer’s purchase of ReViral for an estimated £420 million, Gilead ... central importance of R&D tax credits in leveraging the private investment that drives the UK life sciences ...

Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...

In the latest market close, Gilead Sciences (GILD) reached $115.99, with a +1.47% movement compared to the previous day. This move outpaced the S&P 500's daily loss of 1.76%. Meanwhile, the Dow ...

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415 million. The agreement includes an upfront ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Presenting Sponsors of the event included A+E Networks, Chopard, e.l.f. Beauty, Gilead Sciences, Robert and Dana Kraft, and Bob and Tamar Manoukian. Many thanks to our supporting co-sponsors ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Ligand’s Q4 2024 revenue increased by 52% year-over-year. The company reported a 40% increase in core adjusted EPS for the full year. Ligand ended 2024 with $256 million in cash and investments. Stock ...